The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
Eli Lilly announced results from the COAST-X Phase III study of Taltz in non-radiographic axial spondyloarthritis in patients who had no previous disease-modifying anti-rheumatic drug treatment.
Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz has been a strong performer for the company, bringing in $1.77 billion in revenue last year, but now the company has indicated it intends to make a change in a post-marketing study due to safety concerns.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Celgene Corp. – which is being bought by Bristol-Myers Squibb Co. – reported a better-than-expected fourth-quarter 2018 profit, driven mainly by higher sales of the psoriasis drug Otezla.
Novartis’ 2019 sales and profit guidance disappointed investors seeking more growth from the Swiss drugmaker.
Johnson & Johnson reported better-than-expected fourth-quarter revenue, helped by strong demand for the company’s drugs to treat cancer and psoriasis.
Novartis is taking a treatment for persistent hives into Phase III trials after a mid-stage trial showed that the medication, ligelizumab (QGE031), outperformed Xolair in patients with chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.
The U.S. Food and Drug Administration accepted for priority review the license application for the use of Dupixent in adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis